Sitaram Ghogale

A High‐Sensitivity 10‐Color Flow Cytometric Minimal Residual Disease Assay in B‐Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2‐in‐10⁶and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients

Prashant Tembhare, Papagudi Ganesan Subramanian, Sitaram Ghogale et al. · Cytometry Part B Clinical Cytometry · 2019 · 74 citations · Full text

Evaluation of new markers for minimal residual disease monitoring in B‐cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000–000

Prashant Tembhare, Sitaram Ghogale, Nisha Ghatwai et al. · Cytometry Part B Clinical Cytometry · 2016 · 63 citations · Full text

Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy

Prashant Tembhare, Harshini Sriram, Twinkle Khanka et al. · Journal for ImmunoTherapy of Cancer · 2020 · 41 citations · Full text

A novel and easy <scp>F</scp>xCycle<scp>™</scp> violet based flow cytometric method for simultaneous assessment of <scp>DNA</scp> ploidy and six‐color immunophenotyping

Prashant Tembhare, Yajamanam Badrinath, Sitaram Ghogale et al. · Cytometry Part A · 2015 · 39 citations · Full text

Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients

Prashant Tembhare, Gaurav Narula, Twinkle Khanka et al. · Frontiers in Oncology · 2020 · 32 citations · Full text